5-HT2B antagonists
US9845298B1 · kind B1 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 18, 2017 |
| Grant date | Dec 19, 2017 |
| Priority date | — |
| Expiry date | Aug 18, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D251/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I:and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.